PainReform Ltd. (NASDAQ:PRFX) Short Interest Up 122.3% in June

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 127,699 shares, an increase of 122.3% from the June 15th total of 57,440 shares. Based on an average daily volume of 2,063,956 shares, the short-interest ratio is presently 0.1 days. Currently, 22.4% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

PainReform Price Performance

NASDAQ:PRFX traded down $0.09 during trading hours on Thursday, reaching $1.18. The company had a trading volume of 94,466 shares, compared to its average volume of 1,644,493. PainReform has a 1-year low of $1.16 and a 1-year high of $17.95. The firm has a market cap of $1.03 million, a PE ratio of -0.00 and a beta of 1.05. The business’s 50 day moving average price is $1.58 and its 200-day moving average price is $2.51.

PainReform (NASDAQ:PRFX) last released its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.